Patient reported outcomes (patient-reported outcomes (PROs)) and user experiences of young children with type 1 diabetes using t:slim X2 insulin pump with control-IQ technology
Authors' conclusion
Families utilizing CIQ experienced glycemic benefits coupled with substantial benefits in PROs, documented in surveys and interviews. Families utilizing CIQ had reduced hypoglycemia concerns and parenting stress, and improved quality of life and sleep. These findings demonstrate the benefit of CIQ in young children with type 1 diabetes that goes beyond documented glycemic benefit.
Study context
- Population
- Children with T1D aged 2 to <6 years; guardians completed PRO questionnaires
- Participants
- 102 children
- Comparison
- CIQ vs standard care
- Primary endpoint
- PROs: hypoglycemia concerns, quality of life, parenting stress and sleep (guardian questionnaires)
- Follow-up
- Baseline, 13 and 26 weeks
Methodological details13-week randomized control trial's (RCT) plus 13-week extension, mixed methods (questionnaires and interviews)
- 13-week RCT plus 13-week extension
- Mixed methods (questionnaires and interviews)
Primary result
As reported in the abstract
PRO surveys (5) · 26 weeks
- CIQ vs standard care (SC): P < 0.05
- Repeated measures analyses
Further findings
User-experience interviews (28 families) · 26 weeks
- Endorsed benefits in optimized glycemic control overall and nighttime control
- 28 of 28 families
- Did not note substantial reduction in management burden
- 2/28 families
- Did not state wanting child to continue CIQ
- 4 families
Original publication
Patient reported outcomes (PROs) and user experiences of young children with type 1 diabetes using t:slim X2 insulin pump with control-IQ technology. Diabetes Res Clin Pract. Published 24 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →